tiprankstipranks
Portage Biotech Receives Nasdaq Noncompliance Notice
Company Announcements

Portage Biotech Receives Nasdaq Noncompliance Notice

Story Highlights

Pick the best stocks and maximize your portfolio:

Portage Biotech Inc ( (PRTG) ) has issued an announcement.

Portage Biotech Inc. announced receiving a noncompliance letter from Nasdaq due to insufficient shareholders’ equity, which currently does not affect the listing of its shares. The company plans to submit a compliance plan by January 24, 2025, to address this issue and potentially secure an extension to meet listing requirements. If not accepted, Portage may face delisting but intends to explore strategic alternatives to enhance its financial standing and market position.

More about Portage Biotech Inc

Portage Biotech Inc. is a clinical-stage immuno-oncology company that focuses on developing multi-targeted therapies aimed at extending survival and improving the lives of cancer patients. The company is exploring strategic alternatives and has made the decision to discontinue its iNKT program and pause its adenosine trial program.

YTD Price Performance: -89.53%

Average Trading Volume: 927,668

Technical Sentiment Consensus Rating: Strong Buy

Current Market Cap: $4.27M

For a thorough assessment of PRTG stock, go to TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskPortage Biotech Inc. Appoints New CEO Amid Leadership Change
TheFlyPortage Biotech receives noncompliance notification from Nasdaq
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App